Objective: To identify factors that influence attitudes towards psychopharmacological treatment in patients suffering from schizophrenia and schizoaffective psychoses. Methods: Ninety-two participants in an outpatient psychoeducational program, classed as ”pharmacophobic” or ”pharmacophilic” according to the Drug Attitude Inventory scale, were compared with regard to sociodemographic variables, clinical characteristics, subjective deficit syndrome, illness concepts, knowledge, locus of control, and quality of life. Results: The 59 pharmacophilic and the 33 pharmacophobic patients did not differ significantly with regard to most sociodemographic variables, symptoms, or classic personality traits such as locus of control, self-concept, and quality of life. The only differences concerned hospitalization history (P < 0.05) and statements on the actual, subjective experience of desired and undesired effects of medication (P < 0.01). Conclusions: The impact of subjective experiences with drug treatment on attitudes towards medication and compliance needs to be a main focus of interventions targeting attitudes towards pharmacological treatment.
References
1 Amering M, Katschnig H. Psychopharmaka im Spannungsfeld zwischen Patienten, Angehörigen und Betreuern. In: Platz T (Ed.) Brennpunkte der Schizophrenie - Gesellschaft-Angehörige-Therapie. Springer-Verlag Wien New York; 1993: 223-231
2
Angermeyer M C, Matschinger H.
Public attitudes towards psychotropic drugs: have there been any changes in recent years?.
Pharmacopsychiatry.
2004;
37
152-156
4 Bäuml J, Pitschel-Walz G, Kissling W. Psychoedukative Gruppen bei schizophrenen Psychosen: Spezifische Auswirkungen eines bifokalen Ansatzes auf Krankheitsbewältigung und Rezidivraten im 4-Jahreszeitraum. Ergebnisse der Münchner PIP-Studie. In: Dittmar V, Klein HE, Schön D, eds Die Behandlung schizophrener Menschen. Integrative Therapiemodelle und ihre Wirksamkeit. S. Roderer Verlag Regensburg; 1997: 169-195
5
Bitter I, Chou J C-Y, Ungvari G S, Tang W K, Xiang Z, Iwanami A, Gaszner P.
Prescribing for inpatients with schizophrenia: an international multi-center comparative study.
Pharmacopsychiat.
2003;
36
143-149
6
Cabeza I G, Amador M S, Lopez C A, Gonzalez de Chavez M.
Subjective response to antipsychotics in schizophrenic patients: clinical implications and related factors.
Schizophr Res.
2000;
41
349-355
7
Croghan T W, Tomlin M, Pescosolido B A, Schnittker J, Martin J, Lubelle K eri, Swindle R.
American attitudes toward and willingness to use psychiatric medications.
J Nerv Ment Dis.
2003;
191
166-174
8
Dolder C R, Lacro J P, Dunn L B, Jeste D V.
Antipsychotic medication adherence: is there a difference between typical and atypical agents?.
Am J Psychiatry.
2002;
159
103-108
10
Fenton W S, Blyler C R, Heinssen R K.
Determinants of medication compliance in schizophrenia: empirical and clinical findings.
Schizophr Bull.
1997;
23
637-651
11
Gervin M, Browne S, Garavan J, Roe M, Larkin C, O'Callaghan E.
Dysphoric subjective response to neuroleptics in schizophrenia: relationship to extrapyramidal side effects and symptomatology.
Eur Psychiatry.
1999;
14
405-409
12
Grohmann R, Engel R R, Geissler K H, Rüther E.
Psychotropic drug use in psychiatric inpatients: recent trends and changes over time - data from the AMSP study.
Pharmacopsychiatry.
2004;
37 Suppl 1
S27-38
13 Hiller W, Zaudig M, Mombour W. IDCL/ICD 10 International Diagnostic Checklists. IDCL Internationale Diagnosen Checklisten für ICD-10 und DSM-IV. Verlag Huber Bern; 1995
14
Hofer A, Kemmler G, Eder U, Honeder M, Hummer M, Fleischhacker W W.
Attitudes toward antipsychotics among outpatient clinic attendees with schizophrenia.
J Clin Psychiatry.
2002;
63
49-53
15
Hogan T P, Awad A G, Eastwood R.
A self-report scale predictive of drug compliance in schizophrenia: reliability and discriminative ability.
Psychol Med.
1983;
13
177-183
16
Holzinger A, Löffler W, Müller P, Priebe S, Angermeyer M C.
Subjective illness theory and antipsychotic medication compliance by patients with schizophrenia.
J Nerv Ment Dis.
2002;
190
597-603
17
Jaeger J, Bitter I, Czobor P, Volavka J.
The measurement of subjective experience in schizophrenia: The Subjective Deficit Syndrome Scale.
Compr Psychiatry.
1990;
31 (3)
216-226
21
Keith S J, Kane J M.
Partial compliance and patient consequences in schizophrenia: our patients can do better.
J Clin Psychiatry 2003;.
64;
11
1308-1315
26
Linden M, Nather J, Wilms H U.
Definition, significance and measurement of illness concepts of patients. The Illness Concept Scale (KK-scale) for schizophrenic patients.
Fortschr Neurol Psychiatr.
1988;
56
35-43
27
Löffler W, Kilian R, Toumi M, Angermeyer M C.
Schizophrenic patients' subjective reasons for compliance and noncompliance with neuroleptic treatment.
Pharmacopsychiat.
2003;
36
105-112
28 Lohaus A, Schmitt G M. KKG (Multidimensional Health Locus of Control Scale (MHLC; Wallston, K.A., Wallston, B.S., & DeVellis, R., 1978) - German modified version). Hogrefe Göttingen; 1989
30
Mezzich J E, Ruiperez M A, Perez C, Yoon G, Liu J, Mahmud S.
The Spanish version of the quality of life index. presentation and validation.
J Nerv Ment Dis.
2000;
188 (5)
301-5
31
Noordsy D L, Torrey W C, Mead S, Brunette M, Potenza D, Copeland M E.
Recovery-oriented psychopharmacology: redefining the goals of antipsychotic treatment.
J Clin Psychiatry.
2000 ;
61 (suppl 3)
22-29
34
Rettenbacher M A, Burns T, Kemmler G, Fleischhacker .
Schizophrenia: attitudes of patients and professional carers towards the illness and antipsychotic medication.
Pharmacopsychiatry.
2004;
37
103-109
35
Rossi A, Arduini L, Stratta P, Pallanti S.
Subjective experience and subjective response to neuroleptics in schizophrenia.
Compr Psychiatry.
2000;
41
446-449
36
Ruscher S M, de Wit R, Mazmanian D.
Psychiatric patients' attitudes about medication and factors affecting noncompliance.
Psychiatr Serv.
1997;
48
82-85
